NTRK2 gene fusions are uncommon in pilocytic astrocytoma.
| Title: | NTRK2 gene fusions are uncommon in pilocytic astrocytoma. |
|---|---|
| Authors: | Moreno DA; Molecular Oncology Research Center, Barretos Cancer Hospital, 1331 Antenor Duarte Vilela St, 14784-400, Barretos, SP, Brazil.; Becker AP; James Cancer Hospital and Solove Research Institute Columbus, Ohio, USA.; Scapulatempo-Neto C; Department of Pathology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.; Menezes W; Molecular Oncology Research Center, Barretos Cancer Hospital, 1331 Antenor Duarte Vilela St, 14784-400, Barretos, SP, Brazil.; Sheren J; University of Colorado School of Medicine, Aurora, CO, USA.; Department of Pathology, Colorado Molecular Correlates Laboratory (CMOCO), Molecular Pathology Shared Resource, Cytogenetics - Anschutz Medical Campus - RC1-South, Rm L18-8401A 12801 E 17th Ave, 80045, Aurora, CO, USA.; Walter AM; University of Colorado School of Medicine, Aurora, CO, USA.; Department of Pathology, Colorado Molecular Correlates Laboratory (CMOCO), Molecular Pathology Shared Resource, Cytogenetics - Anschutz Medical Campus - RC1-South, Rm L18-8401A 12801 E 17th Ave, 80045, Aurora, CO, USA.; Clara C; Department of Neurosurgery, Barretos Cancer Hospital, 1331 Antenor Duarte Vilela St, 14784-400, Barretos, SP, Brazil.; Machado HR; Department of Surgery, Ribeirao Preto, Brazil.; Oliveira RS; Department of Surgery, Ribeirao Preto, Brazil.; Neder L; Department of Pathology of Ribeirão Preto Medical School, University of São Paulo (FMRP-USP) - Campus of University of Sao Paulo, 14049-900, Ribeirao Preto, SP, Brazil.; Varella-Garcia M; University of Colorado School of Medicine, Aurora, CO, USA.; Department of Pathology, Colorado Molecular Correlates Laboratory (CMOCO), Molecular Pathology Shared Resource, Cytogenetics - Anschutz Medical Campus - RC1-South, Rm L18-8401A 12801 E 17th Ave, 80045, Aurora, CO, USA.; Reis RM; Molecular Oncology Research Center, Barretos Cancer Hospital, 1331 Antenor Duarte Vilela St, 14784-400, Barretos, SP, Brazil. ruireis.hcb@gmail.com.; Life and Health Sciences Research Institute (ICVS), Medical School, University of Minho, Braga, Portugal. ruireis.hcb@gmail.com.; ICVS/3B's - PT Government Associate Laboratory, Braga, Guimarães, Portugal. ruireis.hcb@gmail.com. |
| Source: | Molecular biology reports [Mol Biol Rep] 2022 Aug; Vol. 49 (8), pp. 7567-7573. Date of Electronic Publication: 2022 Jun 17. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Reidel Country of Publication: Netherlands NLM ID: 0403234 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-4978 (Electronic) Linking ISSN: 03014851 NLM ISO Abbreviation: Mol Biol Rep Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Dordrecht, Boston, Reidel. |
| MeSH Terms: | Astrocytoma*/genetics ; Brain Neoplasms*/genetics ; Brain Neoplasms*/pathology ; Glioma*/genetics; Proto-Oncogene Proteins B-raf/genetics ; Gene Fusion ; Humans ; In Situ Hybridization, Fluorescence |
| Abstract: | Background: Pilocytic astrocytoma is the most frequent pediatric glioma. Despite its overall good prognosis, complete surgical resection is sometimes unfeasible, especially for patients with deep-seated tumors. For these patients, the identification of targetable genetic alterations such as NTRK fusions, raised as a new hope for therapy. The presence of gene fusions involving NTRK2 has been rarely reported in pilocytic astrocytoma. The aim of the present study was to investigate the frequency of NTRK2 alterations in a series of Brazilian pilocytic astrocytomas.; Methods: Sixty-nine pilocytic astrocytomas, previously characterized for BRAF and FGFR1 alterations were evaluated. The analysis of NTRK2 alterations was performed using a dual color break apart fluorescence in situ hybridization (FISH) assay.; Results: NTRK2 fusions were successfully evaluated by FISH in 62 of the 69 cases. Neither evidence of NTRK2 gene rearrangements nor NTRK2 copy number alterations were found.; Conclusions: NTRK2 alterations are uncommon genetic events in pilocytic astrocytomas, regardless of patients' clinicopathological and molecular features.; (© 2022. The Author(s), under exclusive licence to Springer Nature B.V.) |
| References: | Ostrom QT, Patil N, Cioffi G et al (2020) CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neurooncology 22:IV1–IV96. https://doi.org/10.1093/neuonc/noaa200. (PMID: 10.1093/neuonc/noaa200); National Cancer Institute José Alencar Gomes da Silva (INCA) (2013) Cancer in Brazil - Data from the Population Based Registries. In: ISBN 978-85-7318-221-7. https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/cancer-in-brazil-vol4-2013.pdf . Accessed 6 Dec 2021.; Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1. (PMID: 10.1007/s00401-016-1545-127157931); Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Ellison DA D (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/NEUONC/NOAB106. (PMID: 10.1093/NEUONC/NOAB106341850768328013); Collins KL, Pollack IF (2020) Pediatric low-grade gliomas. Cancers (Basel) 12.; Collins VP, Jones DTW, Giannini C (2015) Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol 129:775–788. (PMID: 10.1007/s00401-015-1410-7); Jones DTW, Gronych J, Lichter P et al (2012) MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci 69:1799–1811. (PMID: 10.1007/s00018-011-0898-9); Chatterjee D, Garg C, Singla N, Radotra BD (2018) Desmoplastic non-infantile astrocytoma/ganglioglioma: rare low-grade tumor with frequent BRAF V600E mutation. Hum Pathol 80:186–191. https://doi.org/10.1016/j.humpath.2018.06.005. (PMID: 10.1016/j.humpath.2018.06.00529902580); Breton Q, Plouhinec H, Prunier-Mirebeau D et al (2017) BRAF-V600E immunohistochemistry in a large series of glial and glial–neuronal tumors. Brain and Behavior 7. https://doi.org/10.1002/brb3.641.; Gajjar A, Bowers DC, Karajannis MA et al (2015) Pediatric brain tumors: Innovative genomic information is transforming the diagnostic and clinical landscape. J Clin Oncol 33:2986–2998. (PMID: 10.1200/JCO.2014.59.9217); Guidi M, Giunti L, Buccoliero A et al (2021) Genetic signature and treatment of pediatric highgrade glioma. Mol Clin Oncol 14. https://doi.org/10.3892/mco.2021.2232.; Kurani H, Gurav M, Shetty O et al (2019) Pilocytic astrocytomas: BRAFV600E and BRAF fusion expression patterns in pediatric and adult age groups. Childs Nerv Syst 35:1525–1536. https://doi.org/10.1007/S00381-019-04282-1. (PMID: 10.1007/S00381-019-04282-131321520); Zhang J, Wu G, Miller CP et al (2013) Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45:602–612. https://doi.org/10.1038/ng.2611. (PMID: 10.1038/ng.2611235839813727232); Becker AP, Scapulatempo-Neto C, Carloni AC et al (2015) KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas. J Neuropathol Exp Neurol 74:743–754. https://doi.org/10.1097/NEN.0000000000000213. (PMID: 10.1097/NEN.000000000000021326083571); Jones DTW, Hutter B, Jäger N et al (2013) Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 45:927–932. https://doi.org/10.1038/ng.2682. (PMID: 10.1038/ng.2682238175723951336); Ryall S, Tabori U, Hawkins C (2020) Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun 8. https://doi.org/10.1186/S40478-020-00902-Z.; Tuna M, Amos CI, Mills GB (2019) Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors. Oncotarget 10:2095–2111. (PMID: 10.18632/oncotarget.26777); Drilon A, Hornby Z, Bencardino K et al (2017) Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov 7:400–409. https://doi.org/10.1158/2159-8290.cd-16-1237. (PMID: 10.1158/2159-8290.cd-16-1237281836975380583); Drilon A, Laetsch TW, Kummar S et al (2018) Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children. N Engl J Med 378:731–739. https://doi.org/10.1056/nejmoa1714448. (PMID: 10.1056/nejmoa1714448294661565857389); Mullard A (2018) FDA approves landmark tissue-agnostic cancer drug. Nat Rev Drug Discov 18:7. https://doi.org/10.1038/NRD.2018.226. (PMID: 10.1038/NRD.2018.22630591726); Pattwell SS, Konnick EQ, Liu YJ et al (2020) Neurotrophic Receptor Tyrosine Kinase 2 (NTRK2) Alterations in Low-Grade Gliomas: Report of a Novel Gene Fusion Partner in a Pilocytic Astrocytoma and Review of the Literature. Case Rep Pathol 2020:1–7. https://doi.org/10.1155/2020/5903863. (PMID: 10.1155/2020/5903863); López GY, Perry A, Harding B et al (2019) CDKN2A/B Loss Is Associated with Anaplastic Transformation in a Case of NTRK2 Fusion-positive Pilocytic Astrocytoma. Neuropathol Appl Neurobiol 45:174–178. (PMID: 10.1111/nan.12503); Cocco E, Scaltriti M, Drilon A (2018) NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Reviews Clin Oncol 15:731–747. (PMID: 10.1038/s41571-018-0113-0); Becker AP, Scapulatempo-Neto C, Menezes WP, Clara C, Machado HR, Oliveira RS, Neder LRR (2015) Expression of Methylthioadenosine Phosphorylase (MTAP) in Pilocytic Astrocytomas. Pathobiology 82:84–89. https://doi.org/10.1159/000430956. (PMID: 10.1159/00043095626088413); Schneider H Jr, Raffel C, McComb JG (1992) Benign cerebellar astrocytomas of childhood. Neurosurgery 30:58–62 discussion 62 – 3. https://doi.org/10.1227/00006123-199201000-00011. (PMID: 10.1227/00006123-199201000-000111738456); Ramkissoon SH, Bandopadhayay P, Hwang J, Ramkissoon LA, Greenwald NF, Schumacher SE, O’Rourke R, Pinches N, Ho P, Malkin H, Sinai C, Filbin M, Plant A, Bi WL, Chang MS, Yang E, Wright KD, Manley PE, Ducar M, Alexandrescu S, Lidov H, Delalle I, Goumnerova LK (2017) Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol 19:986–996. https://doi.org/10.1093/NEUONC/NOW294. (PMID: 10.1093/NEUONC/NOW294281047175570190); Clarke M, Mackay A, Ismer B et al (2020) Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discov 10:942–963. https://doi.org/10.1158/2159-8290.CD-19-1030. (PMID: 10.1158/2159-8290.CD-19-1030322383608313225); Dunn B, PharmD D (2020) Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion. J Adv Practitioner Oncol 11:418. https://doi.org/10.6004/jadpro.2020.11.4.9. (PMID: 10.6004/jadpro.2020.11.4.9); Gambella A, Senetta R, Collemi G et al (2020) NTRK Fusions in Central Nervous System Tumors: A Rare. but Worthy Target.; Rohrberg KS, Lassen U (2021) Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology. Drugs 81:445–452. https://doi.org/10.1007/S40265-020-01459-W. (PMID: 10.1007/S40265-020-01459-W33400240); Shulman DS, DuBois SG (2020) The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers. Paediatr Drugs 22:189–197. https://doi.org/10.1007/S40272-020-00380-9. (PMID: 10.1007/S40272-020-00380-931965543); Solomon JP, Linkov I, Rosado A et al (2020) NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol 33:38. https://doi.org/10.1038/S41379-019-0324-7. (PMID: 10.1038/S41379-019-0324-731375766); Deland L, Keane S, Olsson Bontell T et al (2021) Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib. Cancer Biol Ther 22:184–195. https://doi.org/10.1080/15384047.2021.1899573. (PMID: 10.1080/15384047.2021.1899573338204948043191); Ryall S, Zapotocky M, Fukuoka K et al (2020) Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell 37:569–583e5. https://doi.org/10.1016/J.CCELL.2020.03.011. (PMID: 10.1016/J.CCELL.2020.03.011322892787169997); Torre M, Vasudevaraja V, Serrano J et al (2020) Molecular and clinicopathologic features of gliomas harboring NTRK fusions. Acta Neuropathol Commun 8:107. https://doi.org/10.1186/s40478-020-00980-z. (PMID: 10.1186/s40478-020-00980-z326650227362646) |
| Grant Information: | CNPq- 475358/2011-2 National Council for Scientific and Technological Development; FAPESP -2012/19590-0 São Paulo Foundation for Research Support; NIH-P30CA046934 (CCSG Molecular Pathology/Cytogenetics) NIH-P30CA046934 (CCSG Molecular Pathology/Cytogenetics); Coordination for the Improvement of Level Personnel (CAPES, Brazil) Coordination for the Improvement of Level Personnel (CAPES, Brazil) |
| Contributed Indexing: | Keywords: FISH.; Gene fusions; NTRK2; Pilocytic astrocytoma; Tyrosine kinases |
| Substance Nomenclature: | EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) |
| Entry Date(s): | Date Created: 20220617 Date Completed: 20220725 Latest Revision: 20250728 |
| Update Code: | 20260130 |
| DOI: | 10.1007/s11033-022-07567-y |
| PMID: | 35713800 |
| Database: | MEDLINE |
Journal Article